Top Tips on Assessing Molecular Systems of Response
Karol Sikora Medical Director at CancerPartners UK, joins Helen Winsor from Pharma IQ, to discuss new trial design approaches and biomarker application methods coming on stream to drive oncology clinical development. The main focus of this exclusive interview is on assessing molecular signatures of response. First of all, Sikora outlines the drug development pyramid, the main issues surrounding biomarkers and surrogate endpoints in cancer, and how we can evaluate mechanism driven biomarkers. T...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.